首页> 中文期刊> 《中国医药指南》 >血清β2-微球蛋白在急性脑梗死的临床分析

血清β2-微球蛋白在急性脑梗死的临床分析

         

摘要

Objective To investigate the serum β2-MG in patients with acute cerebral infarction before and after treatment were observed. Method  Of electrochemical immunoassay, in 38 cases of acute cerebral infarction acute phase serum levels of β2-MG, 30 patients 1 month after treatment to review, before and after treatment the changes of serum β2-MG and 20 normal controls. Results In patients with acute cerebral infarction β2-MG were significantly higher compared with the control group there was significant difference in treatment was significantly decreased, but still higher than the control group. Conclusions Serum β2-MG in patients with acute cerebral infarction change as conditions change of acute cerebral infarction and efficacy of a supplementary indicators.%  目的 探讨血清的β2-微球蛋白在急性脑梗死患者中治疗前后的变化。方法 用电化学发光免疫法,对38例急性脑梗死患者急性期检测血清的β2-微球蛋白水平,其中30例经治疗后1个月给予复查,比较治疗前后血清β2-微球蛋白的变化,并与20例正常人对照。结果 急性脑梗死患者血清β2-微球蛋白含量明显增高,与对照组比较有显著性差异,治疗后明显下降,但仍比对照组高。结论 血清β2-微球蛋白在急性脑梗死患者中的改变可作为了解急性脑梗死患者病情变化和疗效的一项辅助指标。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号